Pharmacotherapy for Vascular Cognitive Impairment

  title={Pharmacotherapy for Vascular Cognitive Impairment},
  author={Muhammad Umar Farooq and Jiangyong Min and Christopher Goshgarian and Philip B. Gorelick},
  journal={CNS Drugs},
Vascular cognitive impairment (VCI) is the second most common type of dementia after Alzheimer’s disease (AD). Stroke and cardiovascular risk factors have been linked to both AD and VCI and potentially can affect cognitive function in mid and later life. Various pharmacological agents, including donepezil, galantamine, and memantine, approved for the treatment of AD have shown modest cognitive benefits in patients with vascular dementia (VaD). However, their functional and global benefits have… 

Vascular cognitive impairment: pathophysiological mechanisms, insights into structural basis, and perspectives in specific treatments

This review focuses on factors contributing to cerebrovascular disease, neurovascular unit alterations, and novel approaches to cognitive improvement in patients with cognitive decline and the prospective role of a novel complex drug consisting of released–active antibodies to S100 and to endothelial NO synthase in VCI treatment.

Vascular Cognitive Impairment: Information from Animal Models on the Pathogenic Mechanisms of Cognitive Deficits

This review summarizes the information from animal models on the molecular changes that occur in the brain during a cerebral vascular insult and ultimately lead to cognitive deficits in VCI.

Stem cells and vascular dementia: from basic science to the clinic

Evidence suggested that stem cell transplantation could improve the symptoms of cerebral infarction and AD and it may serve as a potential therapy for VD, was summarized both in vitro and in vivo.

Vascular Cognitive Impairment and Dementia

This article gives a broad overview of vascular cognitive impairment and dementia, including epidemiology, pathophysiology, clinical approach, and management, with emphasis on understanding the common underlying types of cerebrovascular disease.

Progression in Vascular Cognitive Impairment: Pathogenesis, Neuroimaging Evaluation, and Treatment

The pathogenesis, neuroimaging evaluation, and treatment of VCI are discussed, which focuses on neurological protection, cerebral blood flow reconstruction, and neurological rehabilitation, such as pharmacological treatment, revascularization, and cognitive training.

Definition and Concept of Vascular Cognitive Impairment

The epidemiology and the evolution of diagnostic criteria for dementia with special emphasis on vascular cognitive impairment are reviewed and the contribution of vascular risk factors to neurodegeneration and novel strategies to prevent or delay cognitive decline are discussed.

Gastrodin and Vascular Dementia: Advances and Current Perspectives

The mechanism and methods of gastrodin in the treatment of vascular dementia are reviewed, providing a reference for clinical therapy.

Meta-Analysis of Naoxintong Capsule for Patients with Vascular Dementia

NXT improved cognitive function in VaD patients, increased the mini-mental state examination (MMSE) score, and significantly improved the daily lives of VaD Patients, and whether NXT was used alone or in combination with western medicine, it could enhance the overall curative effect.

Emerging Concepts in Vascular Dementia: A Review.

Cognitive Impairment in Patients with Stroke.

Despite substantial advances in stroke care, vascular cognitive impairment remains a prominent source of disability. Unlike sensorimotor impairments, cognition often continues to decline after



Rivastigmine for vascular cognitive impairment.

The efficacy of rivastigmine compared with placebo in the treatment of people with vascular cognitive impairment (VCI), vascular dementia or mixed dementia was assessed and no significant difference was found on any outcome measure relevant to cognition, neuropsychiatric symptoms, function or global rating.

Galantamine for vascular cognitive impairment.

  • D. CraigJ. Birks
  • Medicine, Psychology
    The Cochrane database of systematic reviews
  • 2006
The data available at the time of review suggest some advantage over placebo in the areas of cognition and executive functioning in one trial but this was not seen in a second trial which included smaller numbers of relevant patients, and more studies are needed before firm conclusions can be drawn.

Piracetam for dementia or cognitive impairment.

The evidence available from the published literature does not support the use of piracetam in the treatment of people with dementia or cognitive impairment, and no benefit was shown by any of the more specific measures.

Long-Term Treatment with Citicoline May Improve Poststroke Vascular Cognitive Impairment

Citicoline treatment for 12 months in patients with first-ever ischemic stroke is safe and probably effective in improving poststroke cognitive decline and appears to be a promising agent to improve recovery after stroke.

Donepezil in Vascular Dementia: Combined Analysis of Two Large-Scale Clinical Trials

This combined analysis of the largest trial on VaD to date showed that donepezil-treated patients had significant benefits in cognition, global function and ability to perform IADL.

Clinical Trials in Dementia with Propentofylline a

Propentofylline showed statistically significant, clinically relevant improvements over placebo in efficacy assessments, both in Patients with Alzheimer's disease and in patients with vascular dementia, and was also well tolerated.

Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL

Rivastigmine in subcortical vascular dementia An open 22-month study